Daniella Beckman
CIK 1513422 · Chief Financial Officer · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TNGX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE KENDALL SQUARE, BLDG. 1400
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VOR | Director | — | $18.69 | — | $0 | 6 | 2026-06-12 |
| UPB | Director | — | $3.02 | — | $0 | 3 | 2026-06-11 |
| TNGX | Chief Financial Officer | 184,410 | $23.89 | $4.41M | -$198.7K | 8 | 2026-02-04 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 10,842 | $129.46 | $1.40M | $0 | 6 | 2025-07-21 |
| Translate Bio, Inc. (TBIO) Delisted | Director | — | $0.00 | — | $0 | 4 | 2021-09-14 |
| 5:01 Acquisition Corp. (FVAM) Delisted | Director | — | $10.00 | — | $0 | 1 | 2020-10-20 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | SVP, CFO and Treasurer | — | — | — | $0 | 5 | 2014-08-05 |
Recent Filings · Page 2 of 4
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-05 | TNGX | Grant (A) | +26,119 | $0 | EDGAR |
| 2024-10-15 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,242 | $0 | EDGAR |
| 2024-05-28 | VOR | Grant (A) | — | $0 | EDGAR |
| 2024-02-08 | TNGX | Sell (S) | −3,725 | -$46.9K | EDGAR |
| 2024-02-05 | TNGX | Grant (A) | +39,413 | $0 | EDGAR |
| 2023-06-23 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,600 | $0 | EDGAR |
| 2023-06-02 | VOR | Grant (A) | — | $0 | EDGAR |
| 2023-03-02 | TNGX | Grant (A) | +32,842 | $0 | EDGAR |
| 2022-06-30 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,600 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.